Trial Profile
Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs INGAP peptide (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors GMP Companies
- 29 Sep 2014 New trial record